Vyleesi Caffeine Interaction Profile: What You Need to Know Before Dosing

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] It acts primarily at MC3R and MC4R receptors in the central nervous system, modulating dopaminergic and noradrenergic pathways that govern sexual motivation. [2]

Receptor Binding and Central Mechanisms

Unlike phosphodiesterase inhibitors that act peripherally, bremelanotide works centrally. The MC4R pathway in the hypothalamus is the best-characterized target; activation there appears to increase sexual interest independent of hormonal changes. [2] This central mechanism is why cardiovascular and autonomic side effects, including transient blood-pressure elevation, appear reliably in clinical data.

Pharmacokinetic Basics

After a 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration (Cmax) in approximately 1 hour. Mean absolute bioavailability is about 100% for the subcutaneous route. The drug is metabolized via hydrolysis of peptide bonds, not via CYP450 enzymes. [3] That single fact is the bedrock of the caffeine interaction question: because CYP450 is not involved, caffeine, which is primarily metabolized by CYP1A2, does not alter bremelanotide clearance and vice versa.

Does Caffeine Interact with Vyleesi Pharmacokinetically?

No dedicated pharmacokinetic drug-drug interaction study between bremelanotide and caffeine has been published or required by the FDA. The FDA-approved prescribing information lists naltrexone as a substrate interaction of clinical note, not caffeine. [3] Because bremelanotide bypasses CYP450 metabolism entirely, caffeine metabolism via CYP1A2 runs on a completely separate enzymatic track. [4]

Why the CYP450 Pathway Matters

CYP1A2 is the primary enzyme responsible for caffeine N-demethylation. Drugs that inhibit or induce CYP1A2 (for example, fluvoxamine or rifampicin) measurably alter caffeine half-life. [4] Bremelanotide does not inhibit, induce, or compete with CYP1A2 in any published study or FDA submission. Plasma caffeine levels are therefore not expected to rise or fall because of Vyleesi, and bremelanotide clearance is not affected by caffeine intake.

Pharmacokinetic Interaction Risk Rating

The overall pharmacokinetic interaction risk between caffeine and bremelanotide is negligible. This is not a contested finding; it follows directly from the absence of shared enzymatic pathways and is consistent with the broader peptide-pharmacology literature showing that hydrolysis-based peptide clearance rarely intersects with small-molecule CYP metabolism. [5]

The Pharmacodynamic Concern: Stacked Blood-Pressure Effects

Pharmacokinetics aside, pharmacodynamics tell a more clinically relevant story. Both bremelanotide and caffeine raise blood pressure acutely, through entirely different mechanisms.

Bremelanotide's Cardiovascular Signal

The FDA label states that bremelanotide transiently increases systolic blood pressure by approximately 2 mmHg on average, with some patients experiencing larger spikes. [3] In the Phase 3 RECONNECT trials (two replicate studies, combined N = 1,267 premenopausal women with HSDD), cardiovascular adverse events led to treatment discontinuation in a small but measurable subset. [6] The blood-pressure effect typically peaks within 12 hours of dosing.

The prescribing information includes an explicit cardiovascular warning: bremelanotide is contraindicated in patients with known cardiovascular disease and should not be used in women with uncontrolled hypertension. [3]

Caffeine's Cardiovascular Signal

Caffeine antagonizes adenosine A1 and A2A receptors, producing dose-dependent increases in systolic and diastolic blood pressure. A 2012 meta-analysis published in the Journal of Hypertension (22 randomized trials, N = 1,010) found that acute caffeine consumption raised systolic BP by a mean of 3.69 mmHg and diastolic BP by 4.06 mmHg in non-habituated individuals. [7] Habitual coffee drinkers show tolerance, but the acute pressor effect does not disappear entirely, particularly at doses above 200 mg. [7]

Why Stacking Matters on Dosing Day

Adding a 2 mmHg systolic rise from bremelanotide to a 3-4 mmHg rise from caffeine may appear small in isolation. For a patient with baseline blood pressure near the upper limit of Stage 1 hypertension (systolic 129 mmHg), even a combined 5-6 mmHg transient increase pushes readings into Stage 2 territory by American Heart Association definitions. [8] Clinicians prescribing Vyleesi to patients who consume caffeine habitually should perform a resting blood-pressure check at baseline and counsel on limiting high-dose caffeine (more than 200 mg, equivalent to roughly two standard 8-oz cups of drip coffee) on dosing days.

Nausea: The Interaction That Is Not About Drugs

Nausea is the most common adverse effect of bremelanotide. In the RECONNECT Phase 3 trials, 40% of patients reported nausea, and approximately 13% used an antiemetic. [6] Caffeine, particularly on an empty stomach or at higher doses, can independently contribute to gastrointestinal distress through stimulation of gastric acid secretion and increased lower-esophageal sphincter tone. [9]

Practical Guidance for Managing Nausea

The FDA-approved label recommends taking bremelanotide at least 45 minutes before anticipated sexual activity and suggests that eating a low-fat meal before dosing may reduce nausea severity. [3] A high-caffeine beverage (energy drinks, espresso) consumed close to the injection time could worsen nausea symptoms, not through a pharmacological drug interaction, but through additive gastrointestinal irritation.

Patients who are highly sensitive to caffeine-induced nausea should time their caffeine intake at least 2 hours before or after the bremelanotide injection. This is practical advice rather than a formal pharmacological contraindication.

Antiemetic Considerations

If a patient uses ondansetron to control bremelanotide-induced nausea, there is no known interaction between ondansetron and caffeine at therapeutic doses. [10] Metoclopramide, another common antiemetic, does have a mild dopamine-antagonist effect centrally; because bremelanotide itself acts on central melanocortin pathways that intersect with dopaminergic signaling, combining metoclopramide with bremelanotide is theoretically complex, though no clinical study has formally examined this combination. [3]

Can I Drink Alcohol on Vyleesi?

Alcohol is not formally contraindicated by the FDA label, but it is not recommended on dosing days. The prescribing information does not include a specific alcohol-drug interaction study result, which means no dedicated pharmacokinetic data exist. [3]

Physiological Reasoning

Alcohol causes peripheral vasodilation and can lower blood pressure acutely at moderate-to-high doses, which may partially counteract bremelanotide's pressor effect. At the same time, alcohol worsens nausea, delays gastric emptying, and impairs judgment about sexual consent, all of which are clinically relevant concerns. A 2018 review in Alcohol and Alcoholism confirmed that alcohol-induced nausea shares overlapping neurochemical pathways with drug-induced nausea, making additive nausea risk plausible. [11]

Recommended Approach

The HealthRX medical team advises patients to avoid alcohol for at least 2 hours before a bremelanotide dose. This window aligns with the drug's Tmax of approximately 1 hour and the peak nausea window of 1 to 2 hours post-injection. No guideline body has issued a formal quantitative alcohol limit for bremelanotide users, so this recommendation is based on pharmacological reasoning and the labeling caution.

Other Drug Interactions With Bremelanotide

Understanding where caffeine sits in the broader interaction profile helps clinicians contextualize the risk.

Naltrexone

The FDA label specifically notes that bremelanotide delays and reduces naltrexone absorption when the two are taken together. [3] A pharmacokinetic study showed that coadministration reduced naltrexone Cmax by approximately 35%. [3] This is the only named pharmacokinetic interaction in the approved labeling and it occurs via a gastric-motility mechanism, not CYP metabolism.

Indomethacin and Other NSAIDs

No specific NSAID interaction is listed in the bremelanotide prescribing information. [3] However, NSAIDs can raise blood pressure independently through prostaglandin inhibition and sodium retention, which is a pharmacodynamic interaction class worth considering in patients who take NSAIDs regularly and use Vyleesi. [12]

Nitrates and Antihypertensives

Patients on nitrates or antihypertensive therapy are not categorically excluded from bremelanotide use, but the cardiovascular warning in the prescribing information advises special caution. [3] The additive blood-pressure effects of bremelanotide in a patient already on a calcium-channel blocker or beta-blocker require individualized blood-pressure monitoring.

CYP450-Metabolized Drugs

Because bremelanotide does not use CYP450 pathways, coadministration with drugs that are CYP substrates, inhibitors, or inducers, including caffeine via CYP1A2, is not expected to produce pharmacokinetic interactions. [3] This conclusion extends to hormonal contraceptives (primarily CYP3A4 substrates), antidepressants, and antifungals.

Clinical Decision Framework: Caffeine on Vyleesi Dosing Days

The table below organizes caffeine intake levels into a practical risk tier for bremelanotide users. Thresholds are based on the cardiovascular literature and the bremelanotide prescribing information, not on a published clinical trial specifically studying this combination.

| Caffeine Intake on Dosing Day | Approximate Systolic BP Contribution | Risk Tier | Recommendation | |---|---|---|---| | <50 mg (half a cup of tea) | <1 mmHg | Low | No restriction needed | | 50-200 mg (1-2 cups drip coffee) | 1-3 mmHg | Moderate | Acceptable; monitor BP if at risk | | 200-400 mg (3-4 cups or energy drink) | 3-5 mmHg | Elevated | Limit; space intake >2 hours from dose | | >400 mg (high-dose energy products) | 5+ mmHg | High | Avoid on dosing day; discuss with prescriber |

Reference blood-pressure thresholds from the 2017 ACC/AHA Hypertension Guideline define Stage 1 hypertension as systolic 130-139 mmHg and Stage 2 as 140+ mmHg. [8] Patients near these thresholds need individualized discussion.

Who Should Be Extra Cautious?

Patients With Baseline Hypertension

The FDA label categorically contraindicates bremelanotide in women with uncontrolled hypertension. [3] For patients with well-controlled hypertension using antihypertensive medication, the prescribing information requires an individualized risk discussion. These patients should keep caffeine intake below 100 mg on dosing days as a conservative precaution.

High-Sensitivity CYP1A2 Phenotypes

CYP1A2 activity varies substantially across individuals, with poor metabolizers retaining caffeine longer and experiencing prolonged pressor effects. [4] Genetic testing for CYP1A2 polymorphisms is not a standard clinical step before prescribing bremelanotide, but patients who report unusual sensitivity to caffeine (jitteriness or palpitations from a single cup of coffee) may be slow CYP1A2 metabolizers and should be counseled to minimize caffeine on dosing days for that reason alone.

Patients Using Stimulant Medications

Women who take prescription stimulants (amphetamine salts, methylphenidate) for ADHD and who are prescribed bremelanotide represent a population with baseline sympathomimetic cardiovascular load. Caffeine adds further adrenergic stimulation. The combined cardiovascular demand on a bremelanotide dosing day warrants blood-pressure monitoring and a prescriber conversation. [13]

What the FDA Label Says, Verbatim

The bremelanotide prescribing information states: "VYLEESI is contraindicated in patients with cardiovascular disease or uncontrolled hypertension." [3] It further notes: "Transient increases in blood pressure and decreases in heart rate occur following VYLEESI administration." [3] No caffeine-specific language appears in the label because caffeine is not classified as a pharmacokinetic interactant; the pharmacodynamic concern, however, falls squarely within the label's cardiovascular warning language.

Dosing Day Protocol: Practical Summary

A single bremelanotide dose (1.75 mg subcutaneous, abdomen or thigh, at least 45 minutes before sexual activity) produces peak drug exposure at approximately 1 hour post-injection. [3] The nausea risk peaks in that same 1-to-2 hour window. Based on this timeline:

• Limit caffeine to under 200 mg on dosing days if baseline BP is normal.
• Avoid caffeine entirely on dosing days if baseline systolic BP exceeds 120 mmHg or if a prior dose produced significant blood-pressure symptoms.
• Do not use alcohol within 2 hours of injection.
• Eat a low-fat snack before injecting to reduce nausea.
• Wait 24 hours between doses. Repeat dosing within the same day is not permitted per FDA labeling. [3]

A blood-pressure measurement taken 30 minutes after injection is a reasonable clinical checkpoint for patients using Vyleesi for the first time.